Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0325814116
Tue, 19.11.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Miscellaneous/Personnel
Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST
Commercial Highlights
Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the spine market
Strategic expansion op [ … ]
Tue, 25.06.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Study results/Scientific publication
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST
Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next [ … ]
Wed, 17.04.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): AGMEGM
Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST
Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.
The Annual Gen [ … ]
Fri, 08.03.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST
- Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST
Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Bioscienc [ … ]
Thu, 01.02.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Conference
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST
Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present [ … ]
Wed, 31.01.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Regulatory Admission/Market Launch
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand 31.01.2024 / 07:00 CET/CEST
MagnetOs™ Granules becomes the third product in the MagnetOs [ … ]
Thu, 04.01.2024
Kuros Biosciences AG
Kuros Biosciences AG
/ Key word(s): Study results/Preliminary Results
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA 04.01.2024 / 07:00 CET/CEST
New level 1 data from the MAXA [ … ]